Cognitive-Behavioral Therapy for Anxiety in Children With High-Functioning Autism: A Meta-analysis

abstract

BACKGROUND: Anxiety is a common and impairing problem in children and adolescents with autism spectrum disorder (ASD). There is emerging evidence that cognitive-behavioral therapy (CBT) could reduce anxiety in children with high-functioning ASD.

OBJECTIVE: To systematically review the evidence of using CBT to treat anxiety in children and adolescents with ASD. Methods for this review were registered with PROSPERO (CRD42012002722).

METHODS: We included randomized controlled trials published in English in peer-reviewed journals comparing CBT with another treatment, no treatment control, or waitlist control. Two authors independently screened 396 records obtained from database searches and hand searched relevant journals. Two authors independently extracted and reconciled all data used in analyses from study reports.

RESULTS: Eight studies involving 469 participants (252 treatment, 217 comparison) met our inclusion criteria and were included in meta-analyses. Overall effect sizes for clinician- and parent-rated outcome measures of anxiety across all studies were $d = 1.19$ and $d = 1.21$, respectively. Five studies that included child self-report yielded an average $d = 0.68$ across self-reported anxiety.

CONCLUSIONS: Parent ratings and clinician ratings of anxiety are sensitive to detecting treatment change with CBT for anxiety relative to waitlist and treatment-as-usual control conditions in children with high-functioning ASD. Clinical studies are needed to evaluate CBT for anxiety against attention control conditions in samples of children with ASD that are well characterized with regard to ASD diagnosis and co-occurring anxiety symptoms. Pediatrics 2013;132:e1341–e1350

AUTHORS: Denis G. Sukhodolsky, PhD, Michael H. Bloch, MD, MS, Kaitlyn E. Panza, BA, and Brian Reichow, PhD

Yale Child Study Center, Yale University, New Haven, Connecticut

KEY WORDS: autism spectrum disorder, cognitive–behavior therapy, anxiety, children, adolescents, randomized controlled trial, meta-analysis

ABBREVIATIONS
ADIS-C—Anxiety Disorders Interview Schedule–Child Version
ADIS-P—Anxiety Disorders Interview Schedule–Parent Version
ASD—autism spectrum disorder
CASI—Child and Adolescent Symptom Inventory–4 ASD Anxiety Scale
CBT—cognitive-behavior therapy
ES—effect size
OCD—obsessive-compulsive disorder
PARS—Pediatric Anxiety Rating Scale
ROMAS—Revised Children's Manifest Anxiety Scale
SCAS—Spence Children’s Anxiety Scale
TAU—treatment as usual

Dr Sukhodolsky contributed to the development of the review protocol, made decisions about eligibility, drafted the full review, and revised the manuscript; Dr Bloch contributed to the development of the review protocol, extracted and analyzed the data, and reviewed the manuscript; Ms Panza made decisions about eligibility, extracted and analyzed the data, and reviewed the manuscript; Dr Reichow contributed to the development of the review protocol, made decisions about eligibility, extracted and analyzed the data, and drafted the full review; and all authors approved the final manuscript as submitted.

This trial has been registered with PROSPERO (http://www.crd.york.ac.uk/prospero/) (identifier CRD42012002722).

Accepting for publication Aug 27, 2013

Address correspondence to Denis G. Sukhodolsky, PhD, Yale Child Study Center, 530 South Frontage Road, New Haven, CT 06520. E-mail: denis.sukhodolsky@yale.edu

Pediatrics (ISSN Numbers: Print, 0031-4005, Online, 1098-4275).

Copyright © 2013 by the American Academy of Pediatrics

FINANCIAL DISCLOSURE: The authors have indicated they have no financial relationships relevant to this article to disclose.

FUNDING: Supported in part by grants K01 MH079130 (Dr Sukhodolsky) and K23MH091240 (Dr Bloch). Funded by the National Institutes of Health (NIH).

POTENTIAL CONFLICT OF INTEREST: Dr. Reichow receives royalties from an edited book on evidence-based treatments in autism, the other authors have indicated they have no potential conflicts of interest to disclose.
Kanner first described anxiety and excessive fearfulness in his initial account of autism. Anxiety disorders are frequently comorbid in children and adolescents with autism spectrum disorder (ASD), ranging from 40% to 84% for any anxiety disorder; 8% to 63% for specific phobias, 5% to 23% for generalized anxiety, 13% to 29% for social anxiety, and 8% to 27% for separation anxiety disorders. In addition to subjective distress, anxiety contributes to impairment in adaptive functioning and is among the primary reasons for mental health referrals in ASD. Therefore, the development and testing of effective treatments for anxiety in ASD is an important public health priority.

Community surveys indicate that 45% to 83% of children with ASD receive pharmacotherapy. Although selective serotonin reuptake inhibitors have demonstrated efficacy in typically developing children with anxiety disorders, few drug studies have targeted anxiety in children with ASD. Results of a recent trial indicate that citalopram is not effective for repetitive behavior in youth with ASD. Atypical antipsychotics risperidone and aripiprazole have been reported to reduce irritability in children with ASD. However, side effects such as weight gain and metabolic abnormalities underscore the value of nonpharmacological treatments in ASD.

Cognitive-behavioral therapy (CBT) is a first line of treatment for anxiety in typically developing children, and there is emerging evidence that CBT can be helpful for anxiety in children with ASD. In typically developing children with anxiety disorders, CBT has been evaluated in >40 randomized studies showing positive response in 50% to 60% of participants and moderate to large effect sizes (ESs) across studies. Theoretical underpinnings of CBT assume that pathologic anxiety is the result of an interaction between excessive physiologic arousal, cognitive distortions, and avoidance behavior. Accordingly, the core components of CBT include teaching emotion regulation skills aimed at reducing physiologic arousal and maladaptive thinking, followed by systematic exposure to feared situations to eliminate avoidant behavior. In clinical trials, separation and generalized anxiety disorders and social phobia are often grouped together because of the high degree of overlap in symptoms and the distinction from other anxiety disorders (eg, obsessive-compulsive disorder [OCD] and post-traumatic stress disorders). There is emerging evidence that given appropriate modifications, such as breaking anxiety management skills into concrete small steps, adding visual aids and written assignments, and giving a greater role to parents as coaches of new skills, CBT may be also helpful for reducing anxiety in children with high-functioning ASD. The purpose of this review was to systematically appraise the evidence for using CBT to treat anxiety in children and adolescents with higher-functioning ASD.

METHOD

Search Strategy to Identify Studies

We searched the electronic databases of Medline (1946–March Week 3, 2013), PubMed (March 19, 2013), PsycINFO (1967–March Week 3, 2013), and the Cochrane Central Register of Controlled Trials (Issue 2 of 12, February 2013) for relevant trials using search terms (and matching Medical Subject Headings) including “autism,” “Asperger,” “pervasive developmental disorder,” “behavior therapy,” and “cognitive-behavioral therapy.” In addition, we hand searched the references of appropriate papers for this study, as well as any appropriate review articles in this area for citations of additional relevant published and unpublished research. Details of the protocol for this systematic review, including a copy of the search strategy, were registered on PROSPERO (CRD42012002722).

Selection of Studies

Two reviewers independently evaluated the titles and abstracts of the located studies to determine eligibility for inclusion in this meta-analysis using the following criteria: (1) included patient population with a primary diagnosis of ASD, (2) compared a group of patients receiving CBT for anxiety with a group of patients in a control condition (eg, waitlist, treatment as usual [TAU]), and (3) included at least 1 standardized measure of anxiety. Case studies, single-case designs, and qualitative case reports were not considered for this meta-analysis. We did not have an inclusion criterion for the children’s level of cognitive functioning, but all studies included in this meta-analysis were conducted with subjects who had high-functioning ASD, defined as IQ above 70. No published studies to our knowledge have evaluated CBT in children with ASD and IQ below 70.

Variable Definitions and Coding

We coded 9 variables related to research methods, participant characteristics, treatment characteristics, and study results, which are shown in Table 1. For research methods, we coded the sample size, the type of control condition used (eg, waitlist control, no treatment control, alternative treatment), diagnostic assessments, outcome measures (as described below), and risk of bias, which was assessed by using the Jadad scale, which assigns a score of 1 to 5 based on a trial’s randomization, blinding, and attrition. For participant characteristics, we coded the mean age and gender distribution. For treatment characteristics, we extracted the format of CBT used in the study. For the ES, we calculated the
<table>
<thead>
<tr>
<th>Source</th>
<th>Jadad Score</th>
<th>Participants</th>
<th>CBT Format</th>
<th>Control Condition</th>
<th>Diagnostic Assessment</th>
<th>Anxiety Outcome Measure</th>
<th>Anxiety Outcome Measure</th>
<th>ES</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sofronoff et al (2005)</td>
<td>1</td>
<td>N = 71, 65 boys, age range 10–12 y</td>
<td>6 2-h group sessions of CBT with child only or with child and parent</td>
<td>Waitlist</td>
<td>Diagnosis of Asperger syndrome by pediatrician in community</td>
<td>SCAS-P</td>
<td>0.10</td>
<td></td>
</tr>
<tr>
<td>Chalfant et al (2007)</td>
<td>2</td>
<td>N = 47, 35 boys, mean age = 10.8 y, SD = 1.4 y, range 8–13 y</td>
<td>12 2-h group sessions using the Cool Kids manual¹²</td>
<td>Waitlist</td>
<td>Diagnosis of ASD by pediatrician, psychiatrist, or psychologist in community; ADIS-C/P</td>
<td>SCAS-P, SCAS-C</td>
<td>4.34</td>
<td>2.69</td>
</tr>
<tr>
<td>Wood et al (2009)</td>
<td>3</td>
<td>N = 40, 27 boys, mean age = 9.2 y, SD = 1.5 y, range 7–11 y</td>
<td>15 90-min individual sessions using modular format¹³</td>
<td>Waitlist</td>
<td>ADOS, ADI-R, WISC, ADIS-C/P</td>
<td>ADIS-C/P Clinical Severity Rating (blinded to treatment assignment)</td>
<td>2.53</td>
<td></td>
</tr>
<tr>
<td>Sung et al (2011)</td>
<td>2</td>
<td>N = 70, 66 boys, mean age = 11.2 y, SD = 1.8 y, range 9–16 y</td>
<td>16 90-min group sessions using in-house curriculum</td>
<td>Social recreation</td>
<td>ADOS, WISC</td>
<td>MASC-C</td>
<td>1.23</td>
<td>0.03</td>
</tr>
<tr>
<td>McNally Keehn et al (2012)</td>
<td>3</td>
<td>N = 22, 21 boys, mean age = 11.3 y, SD = 1.5 y, range 8–14 y</td>
<td>16 90-min individual sessions using the Coping Cat manual¹⁴</td>
<td>Waitlist</td>
<td>ADOS, ADI-R, WASI, ADIS-P</td>
<td>ADIS-P Interference Rating (blinded to treatment assignment)</td>
<td>1.33</td>
<td>0.95</td>
</tr>
<tr>
<td>Reaven et al (2012)</td>
<td>2</td>
<td>N = 50, 48 boys mean age = 10.4 y, SD = 1.7 y, range 7–14 y</td>
<td>12 90-min group sessions using Face Your Fears curriculum¹⁵</td>
<td>TAU</td>
<td>ADOS, WASI, SCARED</td>
<td>ADIS-P Clinical Severity Rating (blinded to treatment assignment)</td>
<td>0.61</td>
<td></td>
</tr>
<tr>
<td>Storch et al (2015)</td>
<td>3</td>
<td>N = 45, 36 boys, mean age = 8.9 y, SD = 1.3 y, range 7–11 y</td>
<td>16 60- to 90-min sessions using the Behavioral Intervention for Anxiety in Children With Autism Program¹⁶</td>
<td>TAU</td>
<td>ADOS, ADI-R, ADIS-C/P</td>
<td>ADIS-C/P Clinical Severity Rating (blinded to treatment assignment)</td>
<td>1.40</td>
<td>0.91</td>
</tr>
<tr>
<td>White et al (2015)</td>
<td>3</td>
<td>N = 30, 23 boys, mean age = 14.6 y, SD = 1.5 y, range 12–17 y</td>
<td>15 75- to 90-min sessions of individual CBT plus 7 group sessions of social skills training¹⁷</td>
<td>Waitlist</td>
<td>ADOS, ADI-R, WASI, ADIS-C/P</td>
<td>ADIS-C/P Clinical Severity Rating (blinded to treatment assignment)</td>
<td>0.33</td>
<td></td>
</tr>
</tbody>
</table>

ADIS-R, Autism Diagnostic Interview—Revised; ADIS-C/P, Anxiety Disorders Interview Schedule—Child and Parent; ADOS, Autism Diagnostic Observation Schedule; CASI, Child and Adolescent Symptom Inventory; MASC-C, Multidimensional Anxiety Scale for Children—Child; MASC-P, Multidimensional Anxiety Scale for Children—Parent; PARS, Pediatric Anxiety Rating Scale; and ROMAS, Revised Children’s Manifest Anxiety Scale; SCAS-C, Spence Children’s Anxiety Scale—Child Report; SCAS-P, Spence Children’s Anxiety Scale—Parent Report; SCARED, Screen for Child Anxiety Related Emotional Disorders; WASI, Wechsler Abbreviated Scale of Intelligence.

¹² Cool Kids manual. ¹³ Modular format. ¹⁴ Coping Cat manual. ¹⁵ Face Your Fears curriculum. ¹⁶ Behavioral Intervention for Anxiety in Children With Autism Program. ¹⁷ Individual CBT plus 7 group sessions of social skills training.
standardized mean difference between posttreatment means of the treatment and comparison groups using Cohen's d for each outcome category using Wilson's ES calculators based on the formulas provided in Lipsey and Wilson (2001)27 and housed on the Campbell Collaboration web site (http://www.campbellcollaboration.org/resources/ effect_size_input.php). All variables and ES estimates were double coded, and all discrepancies were resolved through mediation and, if necessary, a third opinion.

Outcome Measures

The outcome measures for our analyses were standardized measures of anxiety. We found parent-, clinician-, and child-reported outcomes, which we analyzed separately for this review. Acceptable measures of parent-rated child anxiety included the Spence Children’s Anxiety Scale—Parent Report,28 the Multidimensional Anxiety Scale for Children—Parent,29 and the Child and Adolescent Symptom Inventory—4 ASD Anxiety Scale (CASI).30 Acceptable measures of clinician-rated child anxiety included the Anxiety Disorders Interview Schedule (ADIS)31 and the Pediatric Anxiety Rating Scale (PARS).32 Acceptable measures of child- (self-) reported anxiety included the Spence Children’s Anxiety Scale—Child Report,28 the Multidimensional Anxiety Scale for Children—Child,29 and the Revised Children’s Manifest Anxiety Scale (RCMAS).33

One study34 used 2 clinician-rated measures of anxiety (PARS and ADIS), and 1 study35 used 2 self-report measures of anxiety (RCMAS and Spence Children’s Anxiety Scale [SCAS]). Because measures of anxiety are likely to be highly intercorrelated, we decided against averaging measures within categories. We included the PARS from the Storch et al study because this scale has been designed to measure severity of anxiety in clinical trials and it has been used as a primary outcome in the Child/Adolescent Anxiety Multi-modal Study.9 We decided to include the SCAS from the Chalfant et al study because this measure has been a most commonly used self-report in studies of CBT for anxiety in ASD (see Table 1).

Meta-analytic Procedures

We estimated the difference between treatment and comparison conditions for each study by calculating the standardized mean difference ES. The ES estimate was calculated from the posttreatment scores and standard deviations provided in each study report. We chose the standardized mean difference ES over the weighted mean difference because multiple measures with different scales were used to assess the anxiety outcomes. We then combined results for the studies examining CBT separately for each informant (parent, clinician, and child) using 3 random effects meta-analyses with an inverse variance weighted mean ES. A random effects model was used as our primary synthesis metric for the meta-analysis because there was evidence of heterogeneity between the trials (eg, use of different treatment manuals, use of different outcome measures). We conducted separate meta-analyses for each outcome informant, which are shown in Figs 2, 3, and 4 for parent-rated anxiety, clinician-rated anxiety, and child-reported anxiety, respectively. Given the large variance in ESs across studies, we also conducted a sensitivity analysis by conducting a meta-analysis with the largest ES removed.36 Because recent criticism has been raised about the validity of the Q-statistic as a test of homogeneity in meta-analyses,37 we estimated heterogeneity for each study using I², which estimates the proportion of between-study variance.38

RESULTS

Study Selection

We located 396 studies in our search. Eight studies34,35,39–44 involving 469 participants (252 treatment, 217 comparison) met our inclusion criteria and were included in the analyses. A Preferred Reporting Items for Systematic Reviews and Meta-Analyses45 flow diagram of study selection is shown in Fig 1. The characteristics of the 8 included studies are shown in Table 1.

Parent-Rated Anxiety

Six studies involving 251 children (141 treatment, 110 comparison) comparing CBT with waitlist or TAU for children with ASD included parent-rated anxiety outcomes.34,35,39,40,42,43 As shown in Fig 2, CBT was superior to control conditions for anxiety symptoms in children with ASD as reported by the parents (random effects model ES = 1.19; 95% CI, 0.23 to 2.14; z = 2.44, P = .02; fixed effect model ES = 0.78). However, one study35 had an ES estimate (d = 4.34) that was much larger than that of the other studies (range, d = 0.10–1.23). We explored this effect by conducting a sensitivity analysis by removing the outlier, and we found that the estimated weighted mean ES would decrease from 1.19 to 0.57 (95% CI, 0.16 to 0.97; z = 2.73, P = .006) with the Chalfant et al study removed. We found a moderate degree of heterogeneity for the use of CBT on parent-rated anxiety, Q(5) = 54.8, P < .001; I² = 91%. The heterogeneity with the Chalfant et al study removed for the Q-statistic was not statistically significant, but P, though significantly lower, remained high, Q(4) = 7.46, P = .11; I² = 46%.

Clinician-Rated Anxiety

Five studies involving 166 children with ASD (75 treatment, 91 comparison) comparing CBT with waitlist or TAU with clinician-rated outcomes were located.34,40–43 As shown in Fig 3, CBT was
superior to control conditions for anxiety in children with ASD as reported by the clinicians (random effects model ES = 1.21; 95% CI, 0.50 to 1.97; \( z = 3.36, P = .001 \); fixed effect model ES = 1.10). Again, 1 study\(^4\) had an ES estimate (\( d = 2.53 \)) that was much larger than that of the other studies (range, \( d = 0.33–1.40 \)). We performed a sensitivity analysis to examine this effect by removing the Wood et al study and found a decrease in the estimated weighted mean ES from 1.21 to 0.89 (95% CI, 0.37 to 1.41; \( z = 3.37, P = .001 \)). We found little heterogeneity for the use of CBT in clinician-reported anxiety, \( Q(4) = 17.8, P = .001; I^2 = 77\% \). The heterogeneity with the Wood et al study removed for the \( Q \)-statistic was not statistically significant, although significantly lower, \( I^2 \) remained high, \( Q(3) = 6.34, P = .10; I^2 = 53\% \).

Children-Reported Anxiety

Five studies involving 175 children with ASD (90 treatment, 85 comparison) comparing CBT with waitlist, TAU, or social recreation control condition with child-reported outcomes were located\(^3\),\(^4\),\(^5\),\(^4\),\(^6\) One study\(^3\) did not report the total score for the child-reported outcome (RCMAS), so we averaged all reported RCMAS subscales to calculate the ES estimate that was included in the meta-analysis. Figure 4 depicts a forest plot of the effect of CBT on child-reported anxiety. CBT for anxiety was not significantly different from control conditions as reported by the children (random effects model ES = 0.68 (95% CI, −0.17 to 1.54; \( z = 1.56, P = .12 \); fixed effect model ES = 0.48). Furthermore, this effect appears to be largely driven by 1 study\(^5\) with an ES of 2.69 (ESs in other studies ranges from 0.03 to 0.49). We performed a sensitivity analysis by removing the Chalfant et al study and found that the estimated weighted mean ES decreased from 0.68 to 0.17 (95% CI, −0.13 to 0.47; \( z = 1.09, P = .27 \)). We again found large heterogeneity, \( Q(4) = 34.67, P < .001; I^2 \)
$\bar{I}^2 = 88\%$, with all studies included, but not with the Chalfant et al study removed, $Q(3) = 1.00, P = .80; \bar{I}^2 = 0\%$.

**Publication Bias**

Our final meta-analytic consideration was publication bias. A funnel plot is often used to detect publication bias, which can be analyzed visually. However, analysis of funnel plots with a small number of studies is not recommended because of the significant effects the addition of more studies can have. Therefore, we did not analyze publication bias using funnel plots, but given the large differences in ESs, we would expect additional research to have major effects on the results, thus indicating a strong possibility of publication bias. Given a possibility of publication bias, which we could not statistically examine because of the small number of studies, we also computed the fixed effect model for comparison, which is reported in the text but not shown in the figures.

**DISCUSSION**

We located 8 randomized controlled studies evaluating CBT for anxiety in children and adolescents with ASD. Overall ESs on clinician- and parent-rated outcome measures of anxiety were $d = 1.19$ and $d = 1.21$, respectively, and in the large range. When the outlying studies were removed, the magnitude to these effects decreased to $d = 0.57$ for the parent ratings and $d = 0.89$ for the clinician ratings, but they remained statistically significant (ie, CBT was superior to control conditions). The magnitude of effects of CBT for anxiety relative to waitlist or TAU control conditions in children with ASD is similar to effects of CBT for anxiety in typically developing children. In contrast, most ES estimates of self-report of anxiety yielded small ESs, with 4 of 5 studies showing ES values less than 0.50 and 1 study showing an outlying ES of 2.69. The average $d = 0.68$ across the 5 studies was reduced to $d = 0.19$ when this outlier was removed. Based on these results, we conclude that parent ratings and clinician ratings of anxiety are sensitive to detecting treatment change with CBT for anxiety in children with high-functioning ASD. Although we found significant heterogeneity with all studies included, we deemed moderator analyses inappropriate because of the small number of studies involving mostly small sample sizes. The difference in magnitude of ESs for clinician- and parent-rated anxiety relative to child self-report brings up
a question of validity and reliability of anxiety measures in ASD. There is continuing debate among researchers as to whether anxiety in ASD is a true comorbidity or manifestation of core ASD symptoms.56 Thus, it is conceivable that it might be difficult for parents and clinicians who are asked to rate anxiety in children participating in CBT studies to distinguish anxiety from the core and associated symptoms of ASD. For example, “insistence on sameness” is tied to anxiety due to changes in routines; repetitive behaviors may be performed to reduce anxiety.51 and interruption of stereotypic behaviors often leads to anxiety.52 Two anxiety disorders, OCD and social phobia, may be difficult to diagnose because of their overlap with the core ASD symptoms of repetitive and stereotyped behaviors and impaired social interaction, respectively. Symptoms of generalized anxiety disorder (ie, difficulty concentrating, irritability, and sleep problems) closely resemble common associated features of ASD. For example, children with OCD commonly have recurring, bothersome thoughts that are often directed at removing contaminants or preventing harm. In contrast, children with ASD are less likely to have clearly identifiable obsessions and insight into the senseless nature of a compulsion.53 Repetitive and restricted behaviors tend to decrease in frequency with age and may be less severe in children with higher-functioning autism than in children with autism and intellectual disability.54 Nonetheless, some children with ASD, particularly higher-functioning children, can be diagnosed with OCD and may engage in repetitive behavior to reduce anxiety.55 Although it is often assumed that people with ASD are not interested in social contact, children with ASD may be aware of their social isolation and want it to be different. Awareness of social deficits and the legacy of failure in the social domain may amplify social anxiety in youth with higher-functioning forms of ASD.55–57 In turn, the presence of a co-occurring social anxiety disorder may compound social disability in autism. There is emerging evidence that anxiety disorders can be reliably diagnosed in children with ASD using structured psychiatric interviews.58 Positive response to CBT compared with waitlist and TAU control conditions on parent- and clinician-rated outcomes suggests that parents and clinicians can identify change in anxiety symptoms in children with ASD.

The magnitude of ESs on the child self-report of anxiety was small in 4 of 5 studies, with an average $d = 0.19$ after 1 outlying study was removed. In typically developing children with anxiety disorders, self-report of anxiety is also less sensitive to treatment change than parent and clinician ratings. For example, the average child self-report was $d = 0.36$ in 1 meta-analysis59 and $d = 0.44$ in the other.60 Regarding the discrepancy between parent and child reports of anxiety, it is noteworthy that cross-informant disagreements are a norm rather than the exception in assessment of child psychopathology.61,62 It is possible that children do not perceive their anxiety symptoms as being as troublesome as their parents do, which would attenuate the change in child self-report from pretreatment to posttreatment. Thus, parent ratings commonly reveal greater levels of anxiety in children with ASD than child self-reports.63,64 Alternatively, children may indeed perceive treatments as less helpful than their parents do. In the latter case, it is possible that CBT improves behaviors such as avoidance, a change that parents may interpret as reduction of anxiety but to a lesser extent than the subjective experience of distress that is reflected in self-report. Lastly, the utility of child self-report in children with ASD can be compromised by poor communication skills and cognitive impairment. However, because CBT requires verbal communication, only children capable of participating in verbal therapy were invited to participate in the studies included in this review. Furthermore, internal consistency coefficients of self-report of anxiety in children with high-functioning autism are commonly adequate.65 Although studies included in this meta-analysis did not estimate reliability of child self-reports in their samples, high levels of internal consistency were reported for these measures in other studies. Specifically, in children with high-functioning ASD the Cronbach $\alpha$ coefficients were 0.91 for the SCAS,66 0.92 for the MASC,65 and 0.88 for the RCMAS.67 Thus, it is unlikely that lack of change in child self-report of anxiety is caused by unreliability of child self-reports in ASD. Given that CBT for anxiety is a child-focused intervention that is conducted with the child and requires high levels of motivation and cooperation, child self-report of anxiety appears to be an important source of information about treatment success.

Regarding control conditions, 5 studies compared CBT for anxiety with waitlist, 2 with TAU, and 1 with an attention control condition (see Table 1). Because most children with ASD receive psychoeducational services or pharmacotherapy, subjects randomized to waitlist (as well as subjects randomized to CBT) were allowed to continue their ongoing treatments. Thus, we combined waitlist-controlled studies with studies that used TAU-controlled conditions because these 2 types of control conditions in studies of children with autism appear to be essentially the same. We note that there was considerable heterogeneity among the studies in describing concomitant treatments including providing no information,35,39 reporting a number of
subjects receiving concomitant medication, and reporting medication, psychological, and school-based services. Careful characterization of concomitant treatments including medication and psychoeducational and behavioral interventions in future randomized controlled studies will enable estimating the effects of these concomitant treatments on the magnitude of response to CBT for anxiety.

Only one study compared CBT with an attention control condition that included age-appropriate social and recreational activities (e.g., puzzles, treasure hunt) that were conducted in a group format by therapists who encouraged participation and adherence to group rules similar to that of CBT. There was no difference between CBT and the social recreation control conditions using child self-report measures of anxiety. However, this study was significantly limited by failure to evaluate the levels of the child’s anxiety before the beginning of the treatment, suggesting a possibility that many children in the study were not anxious. Careful evaluation of co-occurring anxiety symptoms and clear criteria for inclusion based on the presence and severity of anxiety are needed to enable interpretation of change after treatment. However, well-designed studies of CBT versus nonspecific treatment control conditions with children with ASD and clinically significant levels of anxiety are needed to evaluate whether reduction of anxiety is caused by CBT rather than attention from a therapist.

All studies reported using structured manuals to deliver CBT for anxiety and provided detailed descriptions of treatments in the method sections. Five treatment manuals have been published (referenced in Table 1) and can be used in clinical practice and dissemination and implementation studies. Most studies provided detailed descriptions of adaptations of CBT for children with ASD or included modules addressing the role of core ASD symptoms in the experience and expression of anxiety in ASD. Although comparison of session-by-session contents of these manualized interventions is beyond the scope of this meta-analysis, it is noteworthy that two studies did not use exposure exercises as part of their CBT interventions. Research with typically developing children and adults suggests that exposure to anxiety-provoking situations is a key component of CBT for anxiety. It is likely that exposure is also a necessary component of CBT for anxiety in children with ASD. Three studies also included large social skills components as part of treatment. Given the core impairment in social functioning and a possibility that anxiety and social deficits in ASD may be interrelated, combining CBT with social skills seems clinically relevant, and these studies support the feasibility of combined treatments. However, randomized studies with larger samples are needed to evaluate the relative contributions of these interventions. Alternatively, studies using single subject or dismantling designs can illuminate the relative effects of multiple behavioral interventions or techniques.

Despite these promising results, the research on CBT for anxiety in ASD has noteworthy methodological limitations in subject characterization, outcome assessment, and use of waitlist or TAU as a control condition. Two studies included children with a preexisting ASD diagnosis that was not confirmed by the study investigators and 2 studies did not report whether children with ASD met criteria for co-occurring anxiety disorder or a cutoff for clinically significant levels of anxiety. Importantly, only 1 study used a matched active comparison control, but this study was also limited by the lack of a comprehensive anxiety assessment at baseline and reliance solely on child self-report of anxiety for outcome evaluation. It is possible that these limitations in subjects’ characterization have contributed to the wide range of ESs observed in this meta-analysis. These limitations can be addressed in the future studies of CBT for anxiety in ASD by using comprehensive assessment for subject characterization with regard to both ASD diagnosis and presence and severity of co-occurring anxiety, comparing CBT with well-designed and clinically relevant alternative treatment conditions that do not include elements of CBT, and reporting concomitant pharmacological, behavioral, and psychoeducational treatments that children receive as they participate in clinical trials.

The meta-analysis was also conducted on a small sample of studies with known methodological flaws; it is likely that the inclusion of additional studies would have significant impact on the results. Additional limitations of this review include the strong possibility of publication bias, which we tried to control for by providing meta-analytic results with 1 study removed, although to our knowledge the collection of randomized controlled trials of CBT for anxiety is the largest collection of a treatment technique for ASD other than that of secretin.

CONCLUSIONS

Eight randomized controlled studies of CBT for anxiety in children and adolescents with ASD were located and yielded significant effects of CBT relative to waitlist or TAU control conditions. Parent ratings and clinician assessments of anxiety but not child self-reports of anxiety were sensitive to treatment change. Future studies should evaluate CBT for anxiety against attention control conditions in samples of children with ASD that are well characterized with regard to ASD diagnosis and co-occurring anxiety symptoms.
REFERENCES


78. Wood JJ, Drabota A. Behavioral Intervention for Anxiety in Children With Autism. Los Angeles, CA: University of California–Los Angeles; 2005

Cognitive-Behavioral Therapy for Anxiety in Children With High-Functioning Autism: A Meta-analysis
Denis G. Sukhodolsky, Michael H. Bloch, Kaitlyn E. Panza and Brian Reichow

Pediatrics 2013;132;e1341
DOI: 10.1542/peds.2013-1193 originally published online October 28, 2013;

Updated Information & Services
including high resolution figures, can be found at:
http://pediatrics.aappublications.org/content/132/5/e1341

References
This article cites 65 articles, 2 of which you can access for free at:
http://pediatrics.aappublications.org/content/132/5/e1341.full#ref-list

Permissions & Licensing
Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:
https://shop.aap.org/licensing-permissions/

Reprints
Information about ordering reprints can be found online:
http://classic.pediatrics.aappublications.org/content/reprints
Cognitive-Behavioral Therapy for Anxiety in Children With High-Functioning Autism: A Meta-analysis
Denis G. Sukhodolsky, Michael H. Bloch, Kaitlyn E. Panza and Brian Reichow
Pediatrics 2013;132;e1341
DOI: 10.1542/peds.2013-1193 originally published online October 28, 2013;

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://pediatrics.aappublications.org/content/132/5/e1341